A tissue kallikrein was purified from rat skeletal muscle. Characterization of the enzyme showed that it has a-N-tosyl-L-arginine methylesterase activity and releases kinin from purified bovine low-Mr kininogen substrate. The pH optimum (9.0) of its esterase activity and the profile of inhibition by serine-proteinase inhibitors are identical with those of purified RUK (rat urinary kallikrein). Skeletal-muscle kallikrein also behaved identically with urinary kallikrein in a radioimmunoassay using a polyclonal anti-RUK antiserum. On Western-blot analysis, rat muscle kallikrein was recognized by affinity-purified monoclonal anti-kallikrein antibody at a position similar to that of RUK (Mr 38000). Immunoreactive-kallikrein levels were measured in skeletal muscles which have different fibre types. The soleus, a slow-contracting muscle with high mitochondrial oxidative-enzyme activity, had higher kallikrein content than did the extensor digitorum longus or gastrocnemius, both fast-contracting muscles with low oxidative-enzyme activity. Streptozotocininduced diabetes reduced muscle weights, but did not alter the level of kallikrein (pg/mg of protein) in skeletal muscle, suggesting that insulin is not a regulator of kallikrein in this tissue. Although the role of kallikrein in skeletal muscle is unknown, its localization and activity in relation to muscle functions and disease can now be studied.
INTRODUCTION
Tissue kallikreins (EC 3.4.21.35 ) are serine proteinases that liberate kinin peptides from kininogen substrates (Miller & Margolius, 1986) . Kinins are potent agonists in vitro of smooth-muscle contraction or relaxation (action is site-specific; Johnson, 1979) and epithelial ion transport (Cuthbert & Margolius, 1982; Leikauf et al., 1985) . Although it remains uncertain what, if any, physiological or pathological role kallikreins may play, recent studies have expanded the list of possible natural substrates. These include apolipoprotein B 100 (Cardin et al., 1984) , atriopeptigens (Currie et al., 1984) , fl-nerve growth factor (Berger & Shooter, 1977) , pro-renin (Sealy et al., 1978) and pro-insulin (ole-Moi Yoi et al., 1979) . Many tissue sites not previously recognized as kallikreincontaining have been found to have a kallikrein that is enzymically and/or immunologically identical with the enzyme found in kidney, pancreas, intestinal mucosa and salivary glands. These new sites include brain , pituitary (Powers & Nasjletti, 1983) , vascular wall (Nolly et al., 1985) and spleen . Identification of kallikrein mRNA in brain , pituitary (Chao et al., 1987) and spleen (Swift et al., 1982) constitutes proof that these tissues synthesize the enzyme. Together, all of these findings raise the possibility that members of the tissue-kallikrein family may serve broader functions than initially perceived.
Studies in isolated cells or tissues suggest that a tissue-kallikrein-like enzyme could be involved in the transmembrane signalling process which mediates some actions of insulin (Jarett et al., 1982; Larner et al., 1982; Seals & Czech, 1980) . Furthermore, studies in vivo have shown that aprotinin, a kallikrein inhibitor, blocks the action of insulin on glucose and amino acid uptake in the human forearm, and that simultaneous bradykinin infusion restores the insulin effect (Dietze et al., 1980) . These reports prompted us to look for tissue kallikrein in skeletal muscle, the principal peripheral target organ for insulin. By using immunoaffinity chromatography with new monoclonal antibodies to rat tissue kallikrein (Woodley et al., 1985) , we have identified and characterized a tissue kallikrein from rat skeletal muscle. Levels of this kallikrein in individual muscles containing different fibre types were measured by radioimmunoassay in normal and STZ-diabetic rats.
MATERIALS AND METHODS Materials
The following materials were obtained from commercial sources: Tos-Arg-OMe, enzyme-grade ( Kallikrein assays Kallikrein-like Tos-Arg-OMease activity was determined as described previously (Margolius et al., 1974) . Samples were incubated with Tos-Arg-0[3H]Me for 30 min at room temperature, and released [3H]methanol was measured. One esterase unit is defined as the amount of enzyme that hydrolyses 1 #smol of Tos-Arg-OMe/min at pH 8.0 and 30 'C. Kinin-generating activity (kininogenase activity) was measured by the method of Shimamoto et al., (1979a) . Purified bovine low-Mr kininogen (12.5 ug/tube) was used as a substrate, and generated kinins were measured by a kinin radioimmunoassay (Shimamoto et al., 1978) . Kallikrein content in individual skeletal muscles was measured by radioimmunoassay (Shimamoto et al.-, 1979b) , modified from the previous procedure by using a..4econd-antiserum (rabbit anti-sheep globulin) precipitation method.
Preparation of muscle extracts
Male Sprague-Dawley rats (300-400 g) were anaesthetized with diethyl ether and perfused through the left heart with 200-250 ml of 0.9% NaCl. Skeletal muscles were dissected from forelimbs, hindlimbs and paravertebral regions. All muscle tissue was carefully cleaned of fat and connective tissue, and then ground in a food processor. The ground tissue was then homogenized in 0.01 M-phosphate buffer, containing 0.1 M-NaCl (pH 7.0), using a Brinkman Polytron tissue homogenizer (full speed; 30 s). The homogenate was centrifuged at 1000 g for 15 min at 4 'C and the supernatant was retained. Sodium deoxycholate was added at a final concentration of 0.5% to the supernatant, which was then incubated at room temperature for 30 min. This incubation mixture was centrifuged at 23 000 g for 20 min at 4 'C in a Beckman JA-20 rotor. The resultant supernatant was stored at -20 'C and used for subsequent purification procedures. The protein concentration of this and all subsequent fractions was determined by the method of Lowry et al. (1951) , with bovine serum albumin as standard.
Purification of skeletal-muscle kallikrein
Pooled muscle extract was thawed and then centrifuged at 5000 g for 30 min at 4 'C to remove any precipitate that had formed. The supernatant was retained and (NH4)2SO4 was added to 30% saturation. After centrifugation at 5000 g for 30 min, the resultant supernatant was retained, and to this (NH4)2SO4 was added at 75% saturation. The pellet obtained after centrifugation at 5000 g for 30 min was dissolved in buffer (0.2 M-NaCl/0.01 M-NaH2PO4, pH 7.0) and dialysed twice against the same buffer for 16 h at 4 'C. Samples were applied to a monoclonal-antibody affinity column (1.5 cm x 15 cm) equilibrated with buffer (0.2 MNaCl/0.01 M-NaH2PO4, pH 6.0). The affinity column was prepared by using antibodies from a clonal hybridoma designated 'V4G6', as described previously by Chao et al. (1984) . Adsorbed protein was eluted with 0.1 M-acetic acid, pH 3.5 (40 ml/h flow rate). Tos-ArgOMease activity was determined in eluted fractions. Fractions with peak activity were pooled for enzymic and immunological characterization.
Western-blot analysis
Western-blot analysis of the purified muscle kallikrein, along with purified RUK, was carried out as previously described in detail (Woodley et al., 1985) . Briefly, electrophoresis was performed in a linear 7.5-17.5% -polyacrylamide gradient gel containing 0.1 % SDS. The proteins were then electrophoretically transferred to nitrocellulose paper (15 V for 18 h at 4°C). The unstained blots were soaked for 1 h at 40°C in a buffer containing 5 % bovine serum albumin, 0.15 M-NaCl, and 0.01 M-Tris/HCl, pH 7.4, to saturate unoccupied proteinbinding sites. Monoclonal antibody (V4D1A) was affinitypurified by kallikrein-agarose chromatography and iodinated as described previously (Shimamoto et al., 1980) . Purified muscle and urinary kallikrein were revealed by autoradiography after direct binding to 1251-labelled monoclonal antibody (Woodley et al., 1985) . Muscle kallikrein levels in normal and diabetic rats Male Sprague-Dawley rats (200-280 g) were studied. Diabetes was induced in 19 rats by intravenous injection of STZ (60 mg/kg body wt.), which was diluted just before injection in 0.1 M-sodium citrate buffer, pH 4.5. Control rats (20 in all) were not injected. After 14 days, diethyl ether-anaesthetized animals were perfused through the left heart with 200-250 ml of 0.9% NaCl.
Individual hindlimb muscles were immediately dissected and processed. Three muscles with different muscle-fibre composition and metabolic properties were chosen. These were soleus, EDL and gastrocnemius. According to the classification of Ariano et al. (1973) Muscles were cleaned of fat and connective tissue and chopped finely with scissors. A 1 g sample of gastrocnemius muscle from each rat was used for kallikrein determination. In the case of the soleus or EDL, pairs of muscles from two to three rats were combined to yield 650-800 mg of tissue. Chopped muscles were homogenized, as described above, in 2-3 ml of Dulbecco's phosphate-buffered saline (0.1 M, pH 7.0, Ca2+-and Mg2+-free). Sodium deoxycholate was added to the homogenate (0.5%, w/v), which was then incubated at room temperature for 30min. The homogenate was centrifuged at 23000 g for 20 min at 4°C (Beckman JA-20 rotor) and the supernatant, containing solubilized protein, was retained. The pellet was homogenized again in 2-3 ml of buffer, treated with sodium deoxycholate, and centrifuged as during the first homogenization.
Supernatants from both extractions were combined and desalted by centrifugal filtration through Sephadex G-25 (Margolius et al., 1974 cut-off of 6000-8000 (Spectrapor membrane tubing; Spectrum Medical Industries, Los Angeles, CA, U.S.A.) being used. Samples were then freeze-dried and reconstituted with 0.1 M-phosphate buffer containing 0.1 M-NaCl, pH 7.0. Kallikrein was measured by radioimmunoawy as described above. Total protein in each sample was measured by the method of Lowry et al. (1951) .
The levels of muscle kallikrein are expressed as pg/mg of protein. Data are expressed as means + S.E.M. The levels of kallikrein in muscle, serum glucose levels, and body and muscle weights of diabetic and control rats were compared by using the two-sided t test for unpaired data.
RESULTS

Characterization of muscle kailikrein
Fractions eluted from the monoclonal-antibody affinity column and which showed highest Tos-ArgOMease activity were pooled. Appropriate dilutions of this enzyme provided a range of concentrations comparable with concentrations of RUK standards used in the radioimmunoassay (Fig. 1) . The displacement of 125I-RUK from polyclonal kallikrein antiserum by serial dilutions of RUK or rat muscle enzyme always showed parallel curves (log-logit transformation of data). Therefore, with an antiserum raised to RUK, the muscle and urinary enzymes showed immunological identity. The purified rat muscle enzyme had a Tos-Arg-OMease activity of 291 esterase units/mg of enzyme, as calculated from the enzyme quantity in the direct radioimmunoassay. This enzyme also released kinin from purified bovine low-Mr kininogen at a rate of 4.9 mg of kinin generated/min per mg of kallikrein.
The pH profiles of Tos-Arg-OMease activity of skeletal-muscle kallikrein and RUK are shown in Fig. 2 . Both enzymes showed optimum activity at pH 9.0, with their profiles being virtually superimposed. The effects of trypsin inhibitors on muscle kallikrein and RUK esterase activities are shown in Fig. 3 . Aprotinin completely inhibited the esterase activity of both kallikreins at inhibitor concentrations from 17 to 170 kallikrein-inhibitory units/ml. Enzyme activities of both were reduced by high concentrations of SBTI (0.17-1.7 mg/ml), but LBTI affected neither muscle nor urinary kallikrein activity at these concentrations. Western-blot analysis of skeletal-muscle kallikrein was performed to demonstrate further specific recognition by tissue-kallikrein antibody. After SDS/polyacrylamidegel electrophoresis and transfer to nitrocellulose paper, blots of muscle and RUK were incubated with 125I-labelled anti-kallikrein monoclonal antibody. Muscle and urinary kallikrein were then revealed by autoradiography (Fig. 4) rats. The reduction in muscle weight was proportional to the reduction in body weight induced by diabetes. Among the three types of hindlimb muscles, soleus showed the highest kallikrein level (258 + 30 pg/mg of protein). The level in gastrocnemius muscle was lowest (56 + 3 pg/mg of protein), being only 20-25% of the soleus concentration. The EDL kallikrein level was intermediate (142 + 14 pg/ml of protein). However, no differences were found in any muscle-kallikrein levels between control and diabetic rats. 
DISCUSSION
We have found that rat skeletal muscle contains a tissue kallikrein that is closely similar to urinary kallikrein with respect to Mr, recognition by polyclonal and monoclonal kallikrein antibodies, pH optimum and susceptibility to inhibitors. The isolated active enzyme displays both Tos-Arg-OMease and kininogenase activities.
Previous biochemical and histochemical studies have found esterase activity in skeletal muscle or muscle fractions. Goldspink et al. (1971) isolated an alkaline proteinase from horse myoglobin. This proteinase had optimal Tos-Arg-OMease activity at pH 8.0-8.5. Both alkaline and neutral esterases have been demonstrated histochemically within muscle fibres of the rat (Holt & Withers, 1957; Romanul, 1964) . We do not know the relation between these esterases and muscle kallikrein. However, some interesting comparisons exist between enzymic activities described in various skeletal muscles and the kallikrein levels we have found. Both Goldspink et al. (1970) and Pluskal & Pennington (1973) found a higher activity of alkaline proteinase in soleus than in EDL in the rat. Using histochemistry, Romanul (1964) also found the highest esterase activity in soleus, and much less in gastrocnemius. In our study, tissue kallikrein was highest in soleus muscle, intermediate in EDL and lowest in gastrocnemius. Romanul (1964) histochemically profiled the activities of esterase, mitochondrial oxidative enzymes, phosphorylase and fl-hydroxybutyrate dehydrogenase in several muscles. He concluded that esterase activity varied directly with the muscle's capacity for oxidative metabolism of glucose and fatty acids, and inversely with the capacity to utilize stored glycogen. The kallikrein levels we found in the soleus, EDL and gastrocnemius suggest the possibility of a similar relation between muscle kallikrein and muscle metabolism. Since muscles with greater oxidative metabolic activity have a richer vascular supply (Romanul, 1965) , and since tissue kallikrein is thought to participate in regulating local blood flow in other organs (Miller & Margolius, 1986) , it is possible that kallikrein in skeletal muscle might function to regulate delivery of oxygen and substrates for energy production. Such a function could explain the observation that a tissue kallikrein inhibitor can reduce the uptake of glucose by exercising human forearm (Dietze et al., 1978) . A recent study, using the isolated perfused rat heart, demonstrated that kinins influence cardiac muscle metabolism by enhancing oxygen delivery to the contracting muscle (Rosen et al., 1983) .
The diabetic state did not produce any change in muscle kallikrein levels in the present study. This is in contrast with observations, by us and others, in other kallikrein-containing tissues. Reductions in renal kallikrein levels and excretion, as well as kallikrein levels of salivary gland and pancreas, have been observed in the rat after 14-28 days of STZ-diabetes (Jaffa et al., 1984; Mayfield et al., 1985; Sakamoto et al., 1985) . Together these data support the contention that kallikreins in different tissues may be under different hormonal and physiological regulation ). The present finding, that the insulin-deficient state did not reduce muscle kallikrein levels, also supports our findings in a recent study of glucose metabolism in isolated skeletal muscle. In the latter study no evidence could be obtained for a role of kallikrein as a direct mediator of insulin action (Shimojo et al., 1984) .
At this time the significance and function of skeletal-muscle kallikrein is unknown. It is also unknown if any other components of the kallikrein-kinin system exist in skeletal muscle. Studies can now explore these questions. Changes in the metabolic, enzymic and physiological characteristics of individual muscles are known to follow such events as exercise training or denervation (Edgerton et al., 1969; Burant et al., 1984; Richter et al., 1984) . Measurement of muscle kallikrein activity under such conditions, and in relation to disease states, might provide some insight into the functions of tissue kallikrein in skeletal muscle.
